Genomic Classification and Prognosis in Acute Myeloid Leukemia

Papaemmanuil, Elli, Gerstung, Moritz, Bullinger, Lars, Gaidzik, Verena I., Paschka, Peter, Roberts, Nicola D., Potter, Nicola E., Heuser, Michael, Thol, Felicitas, Bolli, Niccolo, Gundem, Gunes, Van Loo, Peter, Martincorena, Inigo, Ganly, Peter, Mudie, Laura, McLaren, Stuart, O’Meara, Sarah, Raine, Keiran, Jones, David R., Teague, Jon W., Butler, Adam P., Greaves, Mel F., Ganser, Arnold, Döhner, Konstanze, Schlenk, Richard F., Döhner, Hartmut, Campbell, Peter J.·2016·New England Journal of Medicine
DOI 10.1056/nejmoa1516192

Cited by (1,007)

Items 401–500 of 1,007

  1. Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development
    Michele Stanchina, Deborah Soong, Binbin Zheng-Lin, Justin M. Watts, Justin Taylor · 2020 · Cancers
  2. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
    Kinan Alhallak, Jennifer Sun, Katherine Wasden, Nicole Guenthner, Julie O’Neal, Barbara Muz, Justin A. King, Daniel R. Kohnen, Ravi Vij, Samuel Achilefu et al. · 2021 · Leukemia
  3. A review of treatment options employed in relapsed/refractory AML
    Mohamed Zakee Mohamed Jiffry, Robert A. Kloss, Mohammad A Ahmed-Khan, Felipe Carmona Pires, Nkechi Okam, Prabasha Weeraddana, Dinusha Dharmaratna, Mehndi Dandwani, Kayvon Moin · 2023 · Hematology
  4. CGMega: explainable graph neural network framework with attention mechanisms for cancer gene module dissection
    Hao Li, Zebei Han, Yu Sun, Fu Wang, Pengzhen Hu, Yuang Gao, Xuemei Bai, Shiyu Peng, Chao Ren, Xiang Xu et al. · 2024 · Nature Communications
  5. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling
    M. Wang, Johan Lindberg, Daniel Klevebring, Christer C. Nilsson, Arvind Singh Mer, Mattias Rantalainen, Sören Lehmann, Henrik Grönberg · 2017 · Leukemia
  6. Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape
    PEDRO BORTOLUZZI ESCOBAR DA SILVA, Martín Neumann, Michael P. Schroeder, Sebastian Vosberg, Cornelia Schlee, Konstandina Isaakidis, Jutta Ortiz-Tánchez, Lars R. Fransecky, Teresa Hartung, Seval Türkmen et al. · 2017 · Leukemia
  7. TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
    Matteo Molica, Carla Mazzone, Pasquale Niscola, Paolo de Fabritiis · 2021 · Frontiers in Oncology
  8. Clinical utility of whole-genome sequencing in precision oncology
    Richard Rosenquist, Edwin P. J. G. Cuppen, Reinhard Buettner, Carlos Caldas, Helene Marie-Pierre Dreau, Olivier Elemento, Geert Frederix, Sean Michael Grimmond, Torsten Haferlach, Vaidehi Jobanputra et al. · 2021 · Seminars in Cancer Biology
  9. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia
    Jayastu Senapati, Samuel Urrutia, Sanam Loghavi, Nicholas James Short, Ghayas C. Issa, Abhishek Maiti, Hussein A. Abbas, Naval Guastad Daver, Naveen Pemmaraju, Sherry A. Pierce et al. · 2023 · Blood
  10. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
    Dana Alawieh, Leila Cysique-Foinlan, Christophe Willekens, Aline Renneville · 2024 · Blood Cancer Journal
  11. Droplet Hi-C enables scalable, single-cell profiling of chromatin architecture in heterogeneous tissues
    Lei Chang, Yang Xie, Brett Taylor, Zhaoning Wang, Jiachen Sun, Ethan J. Armand, Shreya V. Mishra, Jie Xu, Melodi Tastemel, Anita Lie et al. · 2024 · Nature Biotechnology
  12. Murine Models of Acute Myeloid Leukaemia
    Marwa Almosailleakh, Juerg Schwaller · 2019 · International Journal of Molecular Sciences
  13. IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
    Claudio Cerchione, Alessandra Romano, Naval Guastad Daver, Courtney Denton Dinardo, Elias Joseph Jabbour, Marina Y Konopleva, Farhad Ravandi‐Kashani, Tapan Mahendra Kadia, Maria Paola Martelli, Alessandro Isidori et al. · 2021 · Frontiers in Oncology
  14. Heterogeneity in refractory acute myeloid leukemia
    Sachi Horibata, Gege Gui, Justin Lack, Christin B. DeStefano, Michael M. Gottesman, Christopher Simon Hourigan · 2019 · Proceedings of the National Academy of Sciences
  15. Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival
    Oscar E. Brück, Olli Dufva, Helena R. Hohtari, Sami Blom, Riku Turkki, Mette Matilda Ilander, Panu E. Kovanen, Céline Pallaud, Pedro Marques Ramos, Hanna Lähteenmäki et al. · 2020 · Blood Advances
  16. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
    Samah Nassereddine, Coen Johannes Gerardus Lap, Faysal Haroun, Imad A. Tabbara · 2017 · Annals of Hematology
  17. The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia
    Jasmin Straube, Victoria Ling, Geoffrey R. Hill, Steven Lane · 2017 · Blood
  18. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting
    Gunnar Juliusson, Martin Jädersten, Stefan Deneberg, Sören Lehmann, Lars Möllgård, Lovisa Wennström, Petar Antunović, Jörg Cammenga, Fryderyk Lorenz, Emma Ölander et al. · 2020 · Blood Advances
  19. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy
    Raphaël Itzykson, Élise Fournier, Céline Berthon, Christoph Röllig, Thorsten Braun, Alice Marceau‐Renaut, Cécile Pautas, Olivier Nibourel, Émilie Lemasle, Jean‐Baptiste Micol et al. · 2021 · Blood
  20. Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
    and for the German-Austrian AMLSG, Richard F. Schlenk, Peter Frech, Daniela Weber, Peter Brossart, Heinz‐August Horst, Doris Maria Kraemer, Gerhard Held, Mark Ringhoffer, Alexander Christoph Burchardt et al. · 2017 · Leukemia
  21. Clinical implications of molecular markers in acute myeloid leukemia
    Sabine Käyser, Mark J. Levis · 2018 · European Journal Of Haematology
  22. Advances in targeted therapy for acute myeloid leukemia
    Jifeng Yu, Peter Y. Z. Jiang, Haowei Sun, Xia Zhang, Zhongxing Jiang, Yingmei Li, Yongping Song · 2020 · Biomarker Research
  23. ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia
    Di Marcantonio, Daniela, Martinez, Esteban, Kanefsky, Joice S., Huhn, Jacklyn M., Gabbasov, Rashid, Gupta, Anushk, Krais, John J., Peri, Suraj, Tan, YinFei, Skorski, Tomasz et al. · 2021 · Molecular Cell
  24. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001
    Geoffrey L. Uy, Sumithra J. Mandrekar, Kristina M. Laumann, Guido Marcucci, Weiqiang Zhao, Mark J. Levis, Heidi D. Klepin, Maria R. Baer, Bayard L. Powell, Peter Westervelt et al. · 2017 · Blood Advances
  25. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
    Sanjay S. Patel, Caleb Ho, Ryan N. Ptashkin, Sam Sadigh, Adam Bagg, Julia Turbiner Geyer, Mina L. Xu, Thomas Prébet, Emily Ferguson Mason, Adam C. Seegmiller et al. · 2019 · Blood Advances
  26. Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
    Jabra G. Zarka, Nicholas James Short, Rashmi Kanagal‐Shamanna, Ghayas C. Issa · 2020 · Genes
  27. A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia
    Anuradha Kirtonia, Gouri Pandya, Gautam Sethi, Amit Kumar Pandey, Bhudev Chandra Das, Manoj Garg · 2020 · Journal of Molecular Medicine
  28. Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy
    Shannon E. Conneely, Alexandra McLean Stevens · 2021 · Current Oncology Reports
  29. XGBLC: an improved survival prediction model based on XGBoost
    Baoshan Ma, Ge Yan, Bingjie Chai, Xiaoyu Hou · 2021 · Bioinformatics
  30. Patterns of mutations in TP53 mutated AML
    John Sutton Welch · 2018 · Best Practice & Research Clinical Haematology
  31. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study
    Brittany Knick Ragon, Olatoyosi M. Odenike, Maria R. Baer, Wendy Stock, Gautam M. Borthakur, Keyur Pravinchandra Patel, Lina Han, Helen Chen, Helen Ma, Loren J. Joseph et al. · 2019 · Clinical Lymphoma Myeloma & Leukemia
  32. Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML
    Swati Garg, Armando Reyes‐Palomares, Lixiazi He, Anne Bergeron, Vincent‐Philippe Lavallée, Sébastien Lemieux, Patrick Gendron, Christian Rohde, Jianglong Xia, P. Jagdhane et al. · 2019 · Blood
  33. Genome Sequencing during a Patient’s Journey through Cancer
    Nangalia, Jyoti, Campbell, Peter J. · 2019 · New England Journal of Medicine
  34. EZH2 in Myeloid Malignancies
    Jenny Rinke, Andrew Chase, Nicholas C.P. Cross, Andreas Hochhaus, Thomas Ernst · 2020 · Cells
  35. Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome
    Lu Jiang, Xue‐Ping Li, Yu-Ting Dai, Bing Chen, Xiangqin Weng, Shu-Min Xiong, Min Zhang, Jinyan Huang, Chen Hui Zhu, Sai‐Juan Chen · 2020 · Proceedings of the National Academy of Sciences
  36. Alterations to DNMT3A in Hematologic Malignancies
    Kartika Venugopal, Yang Feng, Daniil E. Shabashvili, Olga A. Guryanova · 2020 · Cancer Research
  37. Prognostic significance of concurrent gene mutations in intensively treated patients withIDH-mutated AML: an ALFA study
    Matthieu Duchmann, Jean‐Baptiste Micol, Nicolas Duployez, Emmanuel Raffoux, Xavier Thomas, Jean‐Pierre Marolleau, Thorsten Braun, Lionel Adès, Sylvain Chantepie, Émilie Lemasle et al. · 2021 · Blood
  38. Single-cell genomics in AML: extending the frontiers of AML research
    Asiri Ediriwickrema, Andrew J. Gentles, Ravindra Majeti · 2022 · Blood
  39. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia
    for the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG), Verena I. Gaidzik, Daniela Weber, Peter Paschka, Anna Kaumanns, S Krieger, A Corbacioglu, Jan Krönke, Silke Kapp‐Schwoerer, Doris Maria Kraemer et al. · 2017 · Leukemia
  40. Myelodysplastic Syndrome, Acute Myeloid Leukemia, and Cancer Surveillance in Fanconi Anemia
    Sharon A. Savage, Michael Francis Walsh · 2018 · Hematology/Oncology Clinics of North America
  41. Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
    Peter Valent, Wolfgang Kern, Gregor Hoermann, Jelena D. Milosevic Feenstra, Karl Sotlar, Michael Pfeilstöcker, Ulrich Germing, Wolfgang R. Sperr, Andreas Reiter, Dominik Georg Friedrich Wolf et al. · 2019 · International Journal of Molecular Sciences
  42. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia
    Georgina S. Daher-Reyes, Brayan Merchán, Karen W L Yee · 2019 · Expert Opinion on Investigational Drugs
  43. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement
    Fanélie Jouenne, Sylvie Chevret, Emmanuelle Bugnet, Emmanuelle Clappier, Gwenaël Lorillon, Véronique Meignin, Aurélie Sadoux, Shannon Cohen, Alain Haziot, Alexandre How‐Kit et al. · 2019 · European Respiratory Journal
  44. Introducing whole-genome sequencing into routine cancer care: the Genomics England 100 000 Genomes Project
    Clare Turnbull · 2018 · Annals of Oncology
  45. EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients
    Le Zhang, Ying Liu, Mengning Wang, Zhenhai Wu, Na Li, Jinsong Zhang, Chuanwei Yang · 2017 · Journal of Molecular Cell Biology
  46. Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies
    Luiza Handschuh · 2019 · Journal of Oncology
  47. Clonal hematopoiesis as a model for premalignant changes during aging
    David P. Steensma, Benjamin L. Ebert · 2019 · Experimental Hematology
  48. Alterations of T-cell-mediated immunity in acute myeloid leukemia
    Zhuoyan Li, Mary Philip, Paul Brent Ferrell · 2020 · Oncogene
  49. Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
    Andreas Burchert · 2021 · Haematologica
  50. BCOR gene alterations in hematologic diseases
    Paolo Sportoletti, Daniele Sorcini, Brunangelo Falini · 2021 · Blood
  51. The dual role of autophagy in acute myeloid leukemia
    Wonhyoung Seo, Prashanta Silwal, Ik‐Chan Song, Eun‐Kyeong Jo · 2022 · Journal of Hematology & Oncology
  52. Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease
    Michael Spencer Chapman, Alyssa H. Cull, Marioara Felicia Ciuculescu, Erica B. Esrick, Emily Mitchell, Hyunchul Jung, Laura O’Neill, Kirsty Roberts, Margarete A. Fabre, Nicholas Williams et al. · 2023 · Nature Medicine
  53. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms
    Sanam Loghavi, Rashmi Kanagal‐Shamanna, Joseph David Khoury, Leonard Jeffrey Medeiros, Kikkeri N. Naresh, Reza Nejati, Mrinal M. Patnaik · 2023 · Modern Pathology
  54. Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
    Fabio Forghieri, Patrizia Comoli, Roberto Marasca, Leonardo Potenza, Mario Luppi · 2018 · International Journal of Molecular Sciences
  55. Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis
    Madison J. Kelly, Joan So, Amy J. Rogers, Gareth Peter Gregory, Jason Li, Magnus Zethoven, Micah D. Gearhart, Vivian J. Bardwell, Ricky W. Johnstone, Stephin J. Vervoort et al. · 2019 · Nature Communications
  56. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery
    Giorgia Simonetti, Antonella Padella, Ítalo Faria do Valle, Maria Chiara Fontana, Eugenio Fonzi, Samantha Bruno, Carmen Baldazzi, Viviana Guadagnuolo, Marco Manfrini, Anna Ferrari et al. · 2018 · Cancer
  57. High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers
    Hélène Guermouche, Noémie Ravalet, Nathalie Gallay, Caroline Deswarte, Amélie Foucault, Jenny Beaud, Emmanuelle Rault, Emeline Saindoy, Sébastien Lachot, Jean‐Alain Martignoles et al. · 2020 · Blood Advances
  58. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
    Curtis Andrew Lachowiez, Sanam Loghavi, Ken Furudate, Guillermo Montalban Bravo, Abhishek Maiti, Tapan Mahendra Kadia, Naval Guastad Daver, Gautam M. Borthakur, Naveen Pemmaraju, Koji Sasaki et al. · 2021 · Blood Advances
  59. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency
    Zhendong Cao, Krista A. Budinich, Hua Huang, Diqiu Ren, Bin Lu, Zhen Zhang, Qingzhou Chen, Yeqiao Zhou, Yuhan Huang, Fatemeh Alikarami‬ et al. · 2021 · Molecular Cell
  60. Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
    Francesco Maura, Bachisio Ziccheddu, Jenny Xiang, Bhavneet Bhinder, Joel A. Rosiene, Federico Abascal, Kylee H. Maclachlan, Kenneth Wha Eng, Manik Uppal, Feng He et al. · 2023 · Blood Cancer Discovery
  61. Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation
    Yuan-Liang Zhang, Jie-Wen Sun, Yin-Yin Xie, Yan Zhou, Ping Liu, Jia-Chun Song, Chunhui Xu, Lan Wang, Dan Liu, Aining Xu et al. · 2018 · Cell Research
  62. Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group
    Alice Marceau‐Renaut, Nicolas Duployez, Benoît Ducourneau, Myriam Labopin, Arnaud Petit, Alexandra Rousseau, Sandrine Geffroy, Maxime Bucci, Wendy Cuccuini, Odile Fenneteau et al. · 2018 · HemaSphere
  63. Novel Approaches to Acute Myeloid Leukemia Immunotherapy
    Ofrat Beyar‐Katz, Saar I. Gill · 2018 · Clinical Cancer Research
  64. Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC
    Chenying Li, Lei Dong, Rui Jun Su, Ying Bi, Ying Qing, Xiaolan Deng, Yile Zhou, Chao Hu, Mengxia Yu, Hao Huang et al. · 2019 · Haematologica
  65. NPM1 Mutant Mediated PML Delocalization and Stabilization Enhances Autophagy and Cell Survival in Leukemic Cells
    Qin Zou, Shi Tan, Zailin Yang, Qian Zhan, Hongjun Jin, Jingrong Xian, Shuaishuai Zhang, Liyuan Yang, Lu Wang, Ling Zhang · 2017 · Theranostics
  66. The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML
    Jennifer B. Dunlap, Jessica Taft Leonard, Mara W. Rosenberg, Rachel J. Cook, Richard D. Press, Guang Fan, Philipp W. Raess, Brian J. Druker, Elie A. Traer · 2019 · American Journal of Hematology
  67. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
    Jing‐Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, Hongtao Liu, Wei Ding, Hong Zheng, Delong Liu · 2021 · Journal of Hematology & Oncology
  68. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
    Curtis A Lachowiez, Patrick K Reville, Hagop M. Kantarjian, Elias Jabbour, Gautam Borthakur, Naval Daver, Sanam Loghavi, Ken Furudate, Lianchun Xiao, Sherry Pierce et al. · 2022 · The Lancet Haematology
  69. Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
    Nicholas James Short, Daniel Nguyen, Farhad Ravandi · 2023 · Blood Cancer Journal
  70. Preleukemia: one name, many meanings
    Harold Phillip Koeffler, Genevieve Xin Yin Leong · 2016 · Leukemia
  71. Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged Leukemia
    Carly T. Campbell, Jessica N. Haladyna, David A. Drubin, Timothy M. Thomson, Michael J. Maria, Taylor Yamauchi, Nigel J. Waters, Edward J. Olhava, Roy M. Pollock, Jesse Joshua Smith et al. · 2017 · Molecular Cancer Therapeutics
  72. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation
    Thomas A. Schroeder, Christina Rautenberg, Rainer R. Haas, Ulrich Germing, Guido Kobbe · 2017 · International Journal of Hematology
  73. Time to repeal and replace response criteria for acute myeloid leukemia?
    Clara Derber Bloomfield, Elihu H. Estey, Lisa Pleyer, Andre C. Schuh, Eytan M. Stein, Martin S. Tallman, Andrew H. Wei · 2018 · Blood Reviews
  74. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution
    Singhal, Deepak, Wee, Li Yan A., Kutyna, Monika M., Chhetri, Rakchha, Geoghegan, Joel, Schreiber, Andreas W., Feng, Jinghua, Wang, Paul P.-S., Babic, Milena, Parker, Wendy T. et al. · 2019 · Leukemia
  75. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
    Maria Teresa Voso, Richard A. Larson, Dan M. Jones, Guido Marcucci, Thomas W. Prior, Jürgen Krauter, Michael Heuser, Serena Lavorgna, Josep F. Nomdedeu, Susan Michelle Geyer et al. · 2020 · Blood Advances
  76. Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives
    Salvatore Leotta, Annalisa Condorelli, Roberta Sciortino, Giulio Antonio Milone, Claudia Bellofiore, Bruno Garibaldi, Giovanni Schininà, Andrea Spadaro, Alessandra Cupri, Giuseppe Milone · 2022 · Journal of Clinical Medicine
  77. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
    Ghayas C. Issa, Aram Bidikian, Sangeetha Venugopal, Marina Y Konopleva, Courtney Denton Dinardo, Tapan Mahendra Kadia, Gautam M. Borthakur, Elias Joseph Jabbour, Naveen Pemmaraju, Musa E. Yilmaz et al. · 2022 · Blood Advances
  78. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
    Ekaterina Jahn, Maral Saadati, Pierre Fenaux, Marco Gobbi, Gail J. Roboz, Lars Bullinger, Pavlo Lutsik, Anna Riedel, Christoph Plass, Nikolaus Jahn et al. · 2023 · Leukemia
  79. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis
    Roni Tamari, Franck Rapaport, Nan Zhang, Caroline Jane McNamara, Andrew Tucker Kuykendall, David Andrew Sallman, Rami S. Komrokji, Andrea Arruda, Vesna Najfeld, Lonette Sandy et al. · 2019 · Transplantation and Cellular Therapy
  80. E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial
    Bewersdorf, Jan Philipp, Stahl, Maximilian, Taylor, Justin, Mi, Xiaoli, Chandhok, Namrata Sonia, Watts, Justin, Derkach, Andriy, Wysocki, Mateusz, Lu, Sydney X., Bourcier, Jessie et al. · 2023 · Leukemia
  81. Recent advances in the understanding and treatment of acute myeloid leukemia
    Justin M. Watts, Stephen D. Nimer · 2018 · F1000Research
  82. The functions and molecular mechanisms of Tribbles homolog 3 (TRIB3) implicated in the pathophysiology of cancer
    Anam Arif, Ameer A. Alameri, Umer Bin Tariq, Shakeel Ahmed Ansari, Hader I. Sakr, Maytham Talib Qasim, Fadhil Farhood M. Al-joborae, Andrés Alexis Ramírez‐Coronel, Hijran Sanaan Jabbar, Gamal A. Gabr et al. · 2022 · International Immunopharmacology
  83. Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia
    Brunangelo Falini, Maria Paola Martelli · 2023 · American Journal of Hematology
  84. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
    Jad Othman, Charlotte S. Wilhelm-Benartzi, Richard James Dillon, Steven Knapper, Sylvie D. Freeman, Leona M. Batten, Joanna E. Canham, Emily Laura Hinson, Julie Wych, Sophie Betteridge et al. · 2023 · Blood Advances
  85. Epigenetics in myelodysplastic syndromes
    Michael Heuser, Haiyang Yun, Felicitas R. Thol · 2017 · Seminars in Cancer Biology
  86. CIN and Aneuploidy: Different Concepts, Different Consequences
    Klaske M. Schukken, Floris Foijer · 2017 · BioEssays
  87. ASXL1 mutation in clonal hematopoiesis
    Takeshi Fujino, Toshio Kitamura · 2020 · Experimental Hematology
  88. Effect of sorafenib on the outcomes of patients with FLT3‐ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation
    Li Xuan, Yu Wang, Fen Huang, Erlie Jiang, Lan Deng, Bingyi Wu, Zhiping Fan, Xinquan Liang, Na Xu, Jieyu Ye et al. · 2018 · Cancer
  89. A distinct immunophenotype identifies a subset of NPM1‐mutated AML with TET2 or IDH1/2 mutations and improved outcome
    Emily Ferguson Mason, Frank C. Kuo, Robert Paul Hasserjian, Adam C. Seegmiller, Olga Pozdnyakova · 2017 · American Journal of Hematology
  90. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
    Iman Abou Dalle, Courtney Denton Dinardo · 2018 · Therapeutic Advances in Hematology
  91. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 ‐internal tandem duplication genotypes
    Prajwal Chaitanya Boddu, Tapan Mahendra Kadia, Guillermo Garcia‐Manero, Jörge E. Cortes, Mansour Alfayez, Gautam M. Borthakur, Marina Y Konopleva, Elias Joseph Jabbour, Naval Guastad Daver, Courtney Denton Dinardo et al. · 2018 · Cancer
  92. DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia
    Jonathan Bond, Aurore Touzart, Stéphane Leprêtre, Carlos Graux, Mario J. Bargetzi, Ludovic Lhermitte, Guillaume Hypolite, Thibaut Leguay, Yosr Hicheri, Gaëlle Guillerm et al. · 2019 · Haematologica
  93. Transcription factor mutations as a cause of familial myeloid neoplasms
    Jane E. Churpek, Emery H. Bresnick · 2019 · Journal of Clinical Investigation
  94. Acute Myeloid Leukemia: Aging and Epigenetics
    Polina Zjablovskaja, Maria Carolina Florian · 2019 · Cancers
  95. Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms
    Justin Taylor, Xiaoli Mi, Khrystyna North, Moritz Binder, Alexander V. Penson, Terra L. Lasho, Katherine L. B. Knorr, Michael Haddadin, Bo Liu, Joseph Pangallo et al. · 2020 · Blood
  96. Extinguishing the Embers: Targeting AML Metabolism
    Rachel Culp‐Hill, Angelo D’Alessandro, Eric Martin Pietras · 2020 · Trends in Molecular Medicine
  97. Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations
    Oscar Calvillo Arguelles, Alice Carvalhal Schöffel, José‐Mario Capo‐Chichi, Husam Mohamed Abdel-Qadir, Andre C. Schuh, Montserrat Carrillo Estrada, Shiying Liu, Vikas K Gupta, Aaron David Schimmer, Karen W L Yee et al. · 2022 · JACC CardioOncology
  98. In utero origin of myelofibrosis presenting in adult monozygotic twins
    Nikolaos Sousos, Máire Ní Leathlobhair, Christina Simoglou Karali, Eleni Louka, Nicola Bienz, Daniel J. Royston, Sally‐Ann Clark, Angela D. Hamblin, Kieran Howard, Vikram Mathews et al. · 2022 · Nature Medicine
  99. Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia
    Yiman Liu, Qinglan Li, Fatemeh Alikarami‬, Declan R. Barrett, Leila Mahdavi, Hangpeng Li, Sylvia Tang, Tanweer A. Khan, Mayako Michino, Connor Hill et al. · 2022 · Cancer Discovery
  100. Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer
    Carl Johannes Koschmann, Felipe Javier Núñez, Flor Mendez, Jacqueline A. Brosnan‐Cashman, Alan Keith Meeker, Pedro Ricardo Lowenstein, Maria Graciela Castro · 2017 · Cancer Research